GTx
Company

Last deal

$48.5M

Amount

Post-IPO Equity

Stage

26.09.2017

Date

3

all rounds

$163.18M

Total amount

date founded

Financing round

General

About Company
GTx develops small molecules that selectively modulate hormones to create better medicines.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1997

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

GTx is a biopharmaceutical company that discovers, develops, and commercializes small molecules for the treatment of cancer, including breast and prostate cancer, as well as other serious medical conditions such as stress urinary incontinence and Duchenne muscular dystrophy. Their lead product candidate is Enobosarm, and their strategy is focused on the further development of selective androgen receptor modulators. Driven by a team of pioneering individuals, GTx is using new science to create better medicines through established pathways.
Contacts

Contact Email

Phone number

Social url

Similar Companies
999

SynBio

SynBio is a biotechnology company focused on developing innovative medicines known as Biobetters for various diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

Moscow, Russia
InterMune

InterMune

InterMune researches and develops therapies for pulmonology and orphan fibrotic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Brisbane, CA, USA

total rounds

2
Infinity Pharmaceuticals

Infinity Pharmaceuticals

Infinity Pharmaceuticals develops eganelisib, an oral immuno-oncology therapy targeting immune suppression in cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

10

total raised

$538.04M
NeuroMax

NeuroMax

NeuroMax is a Russian biotech company that develops and launches innovative products for treating nervous system diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Moscow, Russia
M&A Details
1

Acquired by

Oncternal Therapeutics

announced date

07.03.2019

Financials

Funding Rounds
5
3

Number of Funding Rounds

$163.18M

Money Raised

Their latest funding was raised on 26.09.2017. Their latest investor Oracle. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Amzak Capital Management

Amzak Capital Management

Amzak Capital Management is a private investment firm that focuses on middle-market, fixed income, real estate and healthcare investments.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance

Location

Boca Raton, FL, USA

count Of Investments

5

count Of Exists

3
Boxer Capital

Boxer Capital

Boxer Capital supports biotech public companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology

Location

Windermere, FL 34786, USA

count Of Investments

91

count Of Exists

7
CAM Capital

CAM Capital

CAM Capital is a VC firm focused on long-term growth.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

New York, NY, USA

total rounds

1

total raised

$1.63M

count Of Investments

25

count Of Exists

1
Abingworth

Abingworth

Abingworth collaborates with entrepreneurs to develop impactful health products in life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital

Location

London, UK

count Of Investments

131

count Of Exists

45
Aisling Capital

Aisling Capital

Aisling Capital is a venture capital firm based in New York that focuses on investing in the pharmaceutical and biotechnology sectors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Venture Capital, Financial Services

Location

New York, NY, USA

count Of Investments

104

count Of Exists

27
Biotechnology Value Fund

Biotechnology Value Fund

Biotechnology Value Fund is a venture capital firm in California that focuses on undervalued investments in the biotechnology sector.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Biotechnology, Venture Capital, Financial Services

Location

San Francisco, CA, USA

count Of Investments

46

count Of Exists

7
Co-Investors
Investors
9
6

Number of lead investors

9

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series E
No
Series E
No
Series E
Oracle

Oracle

Oracle is a cloud services company that offers enterprise IT solutions.

Sector

Software and Computer Services

Subsector

Computer Services

Location

Redwood Shores, Redwood City, CA, USA

total rounds

1

count Of Investments

42

count Of Exists

17
Joseph R. Hyde III

Joseph R. Hyde III

Mr. Hyde, in conjunction with Dr. Wills’ appointment as our Executive Chairman effective March 2, 2015, was appointed as the Board’s Lead Director and currently serves as a member of the Compensation Committee and the Nominating and Corporate Governance Committee. Previously, he served as Chairman of our Board of Directors from November 2000 through February 2015. Since 1989, Mr. Hyde has been the sole stockholder and President of Pittco Holdings, Inc., a private institutional investment company. Since 1996, when Mr. Hyde made a substantial contribution to support the research of one of the company’s founders, Mr. Hyde has been instrumental in helping direct and finance GTx and is our largest stockholder. Mr. Hyde was the Chairman of the Board of Directors of AutoZone, Inc. from 1986 to 1997 and the Chief Executive Officer of AutoZone from 1986 to 1996. From March 2005 to June 2007, Mr. Hyde served as the non-executive chairman of the Board of Directors of AutoZone, Inc., and continues to serve as a member of the Board. He was also Chairman and Chief Executive Officer of Malone & Hyde, Inc., AutoZone’s former parent company, from 1972 until 1988. Mr. Hyde also served as a director of FedEx Corporation from 1977 to 2011. As our largest stockholder and with a long history of serving as both Chairman and Chief Executive Officer of a large publicly-traded company and a member of the board of directors of other public companies, Mr. Hyde has continued to serve as a principal architect of our public company governance structure, and is an influential advisor to senior management on all matters of strategic importance.

count Of Investments

1

count Of Exists

1
MB Venture Partners

MB Venture Partners

MB Venture Partners is a Tennessee-based venture capital firm that invests in life sciences companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Memphis, TN, USA

count Of Investments

82

count Of Exists

25

People

Founders
1
Andrew Romans
Andrew Romans

Andrew Romans

Andrew Romans is the founder of 7BC Venture Capital and Rubicon Venture Capital. Andrew lives by the motto - only invest if you can add value – otherwise, you do not deserve to be in the deal. He has financially outperformed more than 75% of all VCs in Silicon Valley. Before becoming a VC he was a VC-backed entrepreneur and 3x author, former tech VC and M&A investment banker, founder of The Founders Club & cofounder of Georgetown Angels. He is the author of Masters of Corporate Venture Capital, Masters of Blockchain & The Entrepreneurial Bible to Venture Capital, which have been translated into Chinese, Japanese, Italian and Russian by major publishers. Romans raised over $48m for tech startups he founded by the age of 28. He is fluent in English, French & German. MBA Georgetown University, which he completed on scholarship.

current job

7BC Venture Capital
7BC Venture Capital

organization founded

3

Andrew Romans

Employee Profiles
41

Britt Dockery

Director, scientific affairs

Stephen Haynes

Associate director - information technology

Jason Shackelford

Vice president, finance and accounting

Debbie Ellis

Director, human resources at gtx, inc

Andrew Romans

Andrew Romans

Founder & President

Mitchell S. Steiner

Mitchell S. Steiner

Chief Executive Officer and Vice Chairman of Board of Directors

Marc S. Hanover

Marc S. Hanover

President and Chief Operating Officer

Diane Young

Diane Young

Vice President, Chief Medical Officer

Activity

Recent News
0